Veru Inc.

NASDAQ:VERU

Biotechnology

Healthcare
$3.16 +4.33%

+$0.13 today

Market cap
$50.72M
Beta
-1.13
P/E (TTM)
-4.8
EPS (TTM)
-$0.65
52W Low $2.05High $7.33

Volume 0.34M

Average 1.82M

VERU Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Veru Inc.NASDAQ: VERU

Weighted Avg Shares · Q2 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q2 FY2026 weighted avg shares of 21.66M shares rose 47.9% year over year, ahead of the +21.7% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 6.6% from the prior quarter. Over 3 fiscal years it compounded at +22.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +47.9% holds above the trailing-twelve-month pace of +21.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
21.66M+6.6% QoQ
Last fiscal yearSep 2025
14.65M+8.6% YoY
LTMMar 2026
17.82M+21.7% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+47.9%——
1 year+8.6%——
3-year CAGR+22.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
14.65M USD
Year-over-year change
+8.6%
4-year CAGR
+17.7%

Weighted Avg Shares vs competitors

How VERU compares with its peers on the latest reported figures

  • VERU's LTM Mar 2026 weighted avg shares of 17.82M shares is the lowest of the 7 companies compared; the peer median is 28.4M shares.
  • Its year-over-year change of +21.7% is the 5th highest of 7, against a peer median of +35.3%.
  • Over three fiscal years its annual growth of +22.3% compares with a peer median of +30.5%.
VERU Competitors Peer median
Weighted Avg Shares for VERU and competitors
Company Period LTM YoY 3-year CAGR
RNXTRenovoRx, Inc.LTM Mar 202636.65M +42.8%+25.0%
DYAIDyadic International, Inc.LTM Mar 202633.41M +13.2%+4.8%
MAIAMAIA Biotechnology, Inc.LTM Mar 202631.93M +27.8%+51.3%
CELUCelularity Inc.LTM Dec 202524.87M +13.6%+22.3%
ANVSAnnovis Bio, Inc.LTM Mar 202622.96M +82.7%+36.0%
PYPDPolyPid Ltd.LTM Mar 202618.85M +145.8%+132.8%
VERUVeru Inc.LTM Mar 202617.82M +21.7%+22.3%
Peer median (excluding VERU) 28.4M+35.3%+30.5%

Competitors are the stored peer set for VERU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue61.26M39.35M16.3M16.89M0
Cost of Revenue13.33M8.76M8.73M11.03M0
Gross Profit47.93M30.59M7.57M5.85M0
Gross Margin78.2%77.7%46.4%34.7%—
Research & Development32.69M70.65M51.2M12.81M15.59M
Selling, General & Admin20.67M43.17M48.06M31.18M19.94M
Operating Expenses53.36M113.81M101.35M42.77M24.75M
Depreciation & Amortization593.87K209.6K269.87K268.18K152.11K
EBITDA9.75M(79.23M)(89.98M)(36.2M)(35.38M)
EBITDA Margin15.9%-201.3%-552.1%-214.4%—
Operating Income12.97M(83.22M)(93.78M)(36.92M)(24.75M)
Operating Margin21.2%-211.5%-575.5%-218.6%—
Interest Income00000
Interest Expense4.89M4.37M2.43M607.47K0
Other Income / Expenses(8.71M)(580.66K)1.11M(160.93K)9.07M
Income Before Tax4.27M(83.8M)(92.67M)(37.08M)(15.68M)
Pre-Tax Margin7.0%-212.9%-568.6%-219.6%—
Income Tax Expense(3.13M)236.4K480.21K725.1K0
Net Income7.39M(83.78M)(93.15M)(37.8M)(22.73M)
Net Margin12.1%-212.9%-571.6%-223.9%—
EPS (Basic)0.97(10.49)(10.96)(2.80)(1.07)
EPS (Diluted)0.88(10.49)(10.96)(2.80)(1.07)
Weighted Avg Shares7.63M8.01M8.5M13.49M14.65M
Weighted Avg Shares (Diluted)8.38M8.01M8.5M13.49M14.65M

Veru Inc.

NASDAQ:VERU

Intrinsic Alpha fair value

Locked

Current Price

$3.16

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.